(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Scott Tagawa presented a trial in poster summary of the PSMAddition trial. This trial was launched given the proven benefits of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617). 177Lu-PSMA-617 is a high-affinity prostate-specific membrane antigen (PSMA)-targeted radioligand therapy that delivers β-particle radiation to cells that express PSMA, as well as the surrounding microenvironment. While 177Lu-PSMA-617 has recently shown benefit in metastatic castration resistant prostate cancer, other treatment approaches including androgen receptor pathway inhibitors (ARPI) have been utilized in this disease space and metastatic hormone-sensitive prostate cancer (mHSPC) for many years. Notably, ARPI treatment may alter PSMA expression and radiosensitivity. Thus, the PSMAddition trial is designed to assess the efficacy and safety of 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in adults with metastatic hormone-sensitive prostate cancer (mHSPC).